4.6 Review

Cognitive dysfunction in early multiple sclerosis: a review

Journal

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume 111, Issue 6, Pages 359-364

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/qjmed/hcx070

Keywords

-

Funding

  1. Dystonia Ireland
  2. Health Research Board of Ireland [CSA-2012/5]
  3. Irish Institute of Clinical Neuroscience
  4. Biogen
  5. Merck Serono
  6. Novartis
  7. Roche
  8. Genzyme
  9. Bayer

Ask authors/readers for more resources

Cognitive impairment is a common and disabling feature of Multiple Sclerosis (MS), including early MS, and may even predate any physical symptoms. It contributes even more to withdrawal from work than physical disability. Here, we provide an overview of cognitive impairment in MS, particularly in early MS where it is most commonly under-reported and undertreated. We address the presenting features of CI, its impact on quality of life, and its validated assessments (in particular the use of Brief International Cognitive Assessment in MS for use in a clinical setting). We review the insights radiology has given us into the pathogenesis of cognitive impairment in MS, particularly in early CI and in cognitively preserved MS patients. We review current treatments for cognitive impairment, primarily cognitive rehabilitation. We address the evidence for its associated co-morbidities, which may exacerbate or trigger CI, and should therefore be addressed early in the disease course (smoking, alcohol, mood, fatigue and potential co-existing sleep disorders, exercise, and vitamin D). The article supports the importance for early recognition and management of cognitive impairment in MS, before it becomes an established and irreversible entity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available